Depression

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

In this CME article, discover effective strategies for prescribing MAOIs in treating major depressive disorder.

Ketamine-assisted psychotherapy has transformative potential as a groundbreaking approach to mental health that enhances healing through psychedelic experiences.

Debate over using SSRIs in pregnancy in recent FDA focus group raises questions, despite extensive research supporting SSRI use for maternal mental health.

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.

Fava beans emerge as a powerful natural source of L-DOPA, offering potential benefits for mood disorders and Parkinson's disease and holding enriching culinary traditions.

A groundbreaking study links antibiotic exposure to increased depression risk in adolescents, highlighting urinary analysis as a potential screening tool.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

There is a critical link between sleep disorders and psychiatric conditions. In this Special Report, examine effective diagnosis and treatment strategies for better patient outcomes.

Daniel Morehead, MD, critiques the discourse around antidepressants, urging a balanced view of their benefits and risks while addressing patient concerns.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

What is the hidden mental health struggles of affluent youth? In this Tales From the Clinic article, we reveal how wealth can contribute to anxiety, depression, and substance misuse.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

New findings from the RESTORE-LIFE study suggest the potential benefits of VNS treatment in patients with DTD.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.